{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:58:10Z","timestamp":1792069090834,"version":"4.4.0"},"reference-count":171,"publisher":"European Respiratory Society (ERS)","issue":"173","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2024,5,28]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>\n                    Bronchiectasis and nontuberculous mycobacteria (NTM) are intricately intertwined, with NTM capable of being both a cause and consequence of bronchiectatic disease. This narrative review focuses on the common ground of bronchiectasis and NTM pulmonary disease (NTM-PD) in terms of diagnostic approach, underlying risk factors and treatment strategies. NTM-PD diagnosis relies on a combination of clinical, radiological and microbiological criteria. Although their epidemiology is complicated by detection and reporting biases, the prevalence and pathogenicity of NTM species vary geographically, with\n                    <jats:italic>Mycobacterium avium<\/jats:italic>\n                    complex and\n                    <jats:italic>Mycobacterium abscessus<\/jats:italic>\n                    subspecies most frequently isolated in bronchiectasis-associated NTM-PD. Diagnosis of nodular bronchiectatic NTM-PD should prompt investigation of host factors, including disorders of mucociliary clearance, connective tissue diseases and immunodeficiencies, either genetic or acquired. Treatment of NTM-PD in bronchiectasis involves a multidisciplinary approach and considers the (sub)species involved, disease severity and comorbidities. Current guideline-based antimicrobial treatment of NTM-PD is considered long, cumbersome and unsatisfying in terms of outcomes. Novel treatment regimens and strategies are being explored, including rifampicin-free regimens and inclusion of clofazimine and inhaled antibiotics. Host-directed therapies, such as immunomodulators and cytokine-based therapies, might enhance antimycobacterial immune responses. Optimising supportive care, as well as pathogen- and host-directed strategies, is crucial, highlighting the need for personalised approaches tailored to individual patient needs. Further research is warranted to elucidate the complex interplay between host and mycobacterial factors, informing more effective management strategies.\n                  <\/jats:p>","DOI":"10.1183\/16000617.0058-2024","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T05:21:24Z","timestamp":1719984084000},"page":"240058","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Growing from common ground: nontuberculous mycobacteria and bronchiectasis"],"prefix":"10.1183","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7242-0747","authenticated-orcid":false,"given":"Eva","family":"Van Braeckel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3230-0879","authenticated-orcid":false,"given":"C\u00e9dric","family":"Bosteels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"2024102404230499000_33.173.240058.1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.68.805.896"},{"key":"2024102404230499000_33.173.240058.2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.101.6.1605"},{"key":"2024102404230499000_33.173.240058.3","unstructured":"Zweijpfenning SMH . Nontuberculous mycobacteria: turning the antibiotic nightmare around (PhD thesis). Nijmegen, Radboud University, 2024."},{"key":"2024102404230499000_33.173.240058.4","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0015-2023"},{"key":"2024102404230499000_33.173.240058.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055672"},{"key":"2024102404230499000_33.173.240058.6","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00149212"},{"key":"2024102404230499000_33.173.240058.7","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-018-0638-0"},{"key":"2024102404230499000_33.173.240058.8","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1038\/s41598-021-84537-7","article-title":"Geographical distribution and regional differences in 532 clinical isolates of rapidly growing mycobacterial species in Japan","volume":"11","author":"Kamada","year":"2021","journal-title":"Sci Rep"},{"key":"2024102404230499000_33.173.240058.9","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-209729"},{"key":"2024102404230499000_33.173.240058.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00535-2020"},{"key":"2024102404230499000_33.173.240058.11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST"},{"key":"2024102404230499000_33.173.240058.12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pulmoe.2017.12.005","article-title":"Non-tuberculous mycobacterial pulmonary infections","volume":"24","author":"Chalmers","year":"2018","journal-title":"Pulmonology"},{"key":"2024102404230499000_33.173.240058.13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1055\/s-0038-1651493","article-title":"Diagnosis of nontuberculous mycobacteria lung disease","volume":"39","author":"Cowman","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"key":"2024102404230499000_33.173.240058.14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00250-2019"},{"key":"2024102404230499000_33.173.240058.15","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219116"},{"key":"2024102404230499000_33.173.240058.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2005.08.005"},{"key":"2024102404230499000_33.173.240058.17","first-page":"E31","article-title":"Hot tub lung: case report and review of the literature","volume":"121","author":"Gundacker","year":"2022","journal-title":"WMJ"},{"key":"2024102404230499000_33.173.240058.18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202005-2032ST"},{"key":"2024102404230499000_33.173.240058.19","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.chest.2021.03.066","article-title":"Diagnosis and evaluation of hypersensitivity pneumonitis: CHEST guideline and expert panel report","volume":"160","author":"P\u00e9rez","year":"2021","journal-title":"Chest"},{"key":"2024102404230499000_33.173.240058.20","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2008.110957"},{"key":"2024102404230499000_33.173.240058.21","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1186\/s12879-019-4683-y","article-title":"Clinical relevance of pulmonary non-tuberculous mycobacterial isolates in three reference centres in Belgium: a multicentre retrospective analysis","volume":"19","author":"Vande Weygaerde","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2024102404230499000_33.173.240058.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2014.10.002"},{"key":"2024102404230499000_33.173.240058.23","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1055\/s-0038-1660864","article-title":"Geographic distribution of nontuberculous mycobacteria isolated from clinical specimens: a systematic review","volume":"39","author":"Zweijpfenning","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"key":"2024102404230499000_33.173.240058.24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00537-2016"},{"key":"2024102404230499000_33.173.240058.25","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1159\/000518328","article-title":"Prevalence and clinical characteristics of nontuberculous mycobacteria in patients with bronchiectasis: a systematic review and meta-analysis","volume":"100","author":"Zhu","year":"2021","journal-title":"Respiration"},{"key":"2024102404230499000_33.173.240058.26","doi-asserted-by":"crossref","first-page":"e0153123","DOI":"10.1128\/jcm.01531-23","article-title":"This is giving me a complex: a practical attempt to streamline nontuberculous mycobacteria nomenclature for clinical purposes","volume":"62","author":"Wengenack","year":"2024","journal-title":"J Clin Microbiol"},{"key":"2024102404230499000_33.173.240058.27","first-page":"661","article-title":"Prevalence of nontuberculous mycobacteria in patients with bronchiectasis: a meta-analysis","volume":"10","author":"Chu","year":"2014","journal-title":"Arch M\u00e9d Sci"},{"key":"2024102404230499000_33.173.240058.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2013.03.018"},{"key":"2024102404230499000_33.173.240058.29","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.chest.2023.06.014","article-title":"Risk factors for nontuberculous mycobacterial pulmonary disease a systematic literature review and meta-analysis","volume":"164","author":"Loebinger","year":"2023","journal-title":"Chest"},{"key":"2024102404230499000_33.173.240058.30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201502-0387OC"},{"key":"2024102404230499000_33.173.240058.31","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1333573"},{"key":"2024102404230499000_33.173.240058.32","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0606-6"},{"key":"2024102404230499000_33.173.240058.33","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201772"},{"key":"2024102404230499000_33.173.240058.34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10096-018-3402-8","article-title":"Risk factors and secondary care utilisation in a primary care population with non-tuberculous mycobacterial disease in the UK","volume":"38","author":"Axson","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024102404230499000_33.173.240058.35","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0120"},{"key":"2024102404230499000_33.173.240058.36","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200303-365OC"},{"key":"2024102404230499000_33.173.240058.37","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201212-2197OC"},{"key":"2024102404230499000_33.173.240058.38","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1164\/rccm.201906-1219OC","article-title":"Airway mucus hyperconcentration in non\u2013cystic fibrosis bronchiectasis","volume":"201","author":"Ramsey","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404230499000_33.173.240058.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2216474"},{"key":"2024102404230499000_33.173.240058.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1502191"},{"key":"2024102404230499000_33.173.240058.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2009.12.001"},{"key":"2024102404230499000_33.173.240058.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2014.08.002"},{"key":"2024102404230499000_33.173.240058.43","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200207-678OC"},{"key":"2024102404230499000_33.173.240058.44","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01257-09"},{"key":"2024102404230499000_33.173.240058.45","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.7.3467-3470.2005"},{"key":"2024102404230499000_33.173.240058.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2014.11.003"},{"key":"2024102404230499000_33.173.240058.47","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00089-4"},{"key":"2024102404230499000_33.173.240058.48","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2013.19"},{"key":"2024102404230499000_33.173.240058.49","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201206-1035OC"},{"key":"2024102404230499000_33.173.240058.50","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01478-2016"},{"key":"2024102404230499000_33.173.240058.51","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200805-686OC"},{"key":"2024102404230499000_33.173.240058.52","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1164\/rccm.201306-1059LE","article-title":"A familial syndrome of pulmonary nontuberculous mycobacteria infections","volume":"188","author":"Leung","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404230499000_33.173.240058.53","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201612-2479OC"},{"key":"2024102404230499000_33.173.240058.54","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2422-8"},{"key":"2024102404230499000_33.173.240058.55","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00545-0"},{"key":"2024102404230499000_33.173.240058.56","doi-asserted-by":"publisher","DOI":"10.3201\/eid1510.090310"},{"key":"2024102404230499000_33.173.240058.57","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1711.2000.00933.x"},{"key":"2024102404230499000_33.173.240058.58","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jfma.2011.11.004","article-title":"Immune defects in active mycobacterial diseases in patients with primary immunodeficiency diseases (PIDs)","volume":"110","author":"Lee","year":"2011","journal-title":"J Formos Med Assoc"},{"key":"2024102404230499000_33.173.240058.59","doi-asserted-by":"publisher","DOI":"10.1086\/587669"},{"key":"2024102404230499000_33.173.240058.60","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000229482.27398.ad"},{"key":"2024102404230499000_33.173.240058.61","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-007-9040-z"},{"key":"2024102404230499000_33.173.240058.62","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00590-2020"},{"key":"2024102404230499000_33.173.240058.63","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026407815946"},{"key":"2024102404230499000_33.173.240058.64","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4269\/ajtmh.16-0905","article-title":"Association of interferon-\u03b3 receptor-1 gene polymorphism with nontuberculous mycobacterial lung infection among Iranian patients with pulmonary disease","volume":"97","author":"Farnia","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"2024102404230499000_33.173.240058.65","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120222"},{"key":"2024102404230499000_33.173.240058.66","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/ijms25010515","article-title":"Anticytokine autoantibodies in infectious diseases: a practical overview","volume":"25","author":"Arts","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2024102404230499000_33.173.240058.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2014.11.002"},{"key":"2024102404230499000_33.173.240058.68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105093241906"},{"key":"2024102404230499000_33.173.240058.69","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200690"},{"key":"2024102404230499000_33.173.240058.70","first-page":"1505","article-title":"Mycobacterium abscessus infection during ustekinumab treatment in Crohn's disease: a case report and review of the literature","volume":"12","author":"Shim","year":"2018","journal-title":"J Crohn\u2019s Colitis"},{"key":"2024102404230499000_33.173.240058.71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1065"},{"key":"2024102404230499000_33.173.240058.72","doi-asserted-by":"publisher","DOI":"10.1086\/380453"},{"key":"2024102404230499000_33.173.240058.73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111160"},{"key":"2024102404230499000_33.173.240058.74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-452482"},{"key":"2024102404230499000_33.173.240058.75","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/cid\/cix372","article-title":"Repurposing QuantiFERON for detection of neutralizing interferon-\u03b3 autoantibodies in patients with nontuberculous mycobacterial infections","volume":"65","author":"Su\u00e1rez","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024102404230499000_33.173.240058.76","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cyto.2014.01.005","article-title":"Levels of anti-cytokine antibodies may be elevated in patients with pulmonary disease associated with non-tuberculous mycobacteria","volume":"66","author":"Kim","year":"2014","journal-title":"Cytokine"},{"key":"2024102404230499000_33.173.240058.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.10.026"},{"key":"2024102404230499000_33.173.240058.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.02.017"},{"key":"2024102404230499000_33.173.240058.79","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/1469-0691.12641","article-title":"Mycobacterial infections in solid organ transplant recipients","volume":"20","author":"Meije","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2024102404230499000_33.173.240058.80","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1329-4"},{"key":"2024102404230499000_33.173.240058.81","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1407-7"},{"key":"2024102404230499000_33.173.240058.82","doi-asserted-by":"publisher","DOI":"10.1086\/420746"},{"key":"2024102404230499000_33.173.240058.83","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2011.02076.x"},{"key":"2024102404230499000_33.173.240058.84","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1513\/AnnalsATS.201804-245OC","article-title":"Association between inhaled corticosteroid use and pulmonary nontuberculous mycobacterial infection","volume":"15","author":"Liu","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2024102404230499000_33.173.240058.85","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00037-2017"},{"key":"2024102404230499000_33.173.240058.86","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46095"},{"key":"2024102404230499000_33.173.240058.87","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2280"},{"key":"2024102404230499000_33.173.240058.88","doi-asserted-by":"crossref","first-page":"793453","DOI":"10.3389\/fmed.2022.793453","article-title":"Healthcare utilization and medical cost of gastrointestinal reflux disease in non-tuberculous mycobacterial pulmonary disease: a population-based study, South Korea, 2009\u20132017","volume":"9","author":"Kim","year":"2022","journal-title":"Front Med"},{"key":"2024102404230499000_33.173.240058.89","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.chest.2022.08.2228","article-title":"Gastroesophageal reflux disease increases susceptibility to nontuberculous mycobacterial pulmonary disease","volume":"163","author":"Kim","year":"2023","journal-title":"Chest"},{"key":"2024102404230499000_33.173.240058.90","doi-asserted-by":"publisher","DOI":"10.4065\/74.1.45"},{"key":"2024102404230499000_33.173.240058.91","doi-asserted-by":"publisher","DOI":"10.1038\/nri2318"},{"key":"2024102404230499000_33.173.240058.92","doi-asserted-by":"crossref","first-page":"17180","DOI":"10.1038\/s41598-022-21511-x","article-title":"Severity of underweight affects the development of nontuberculous mycobacterial pulmonary disease; a nationwide longitudinal study","volume":"12","author":"Kang","year":"2022","journal-title":"Sci Rep"},{"key":"2024102404230499000_33.173.240058.93","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00408-014-9565-x","article-title":"The impact of low subcutaneous fat in patients with nontuberculous mycobacterial lung disease","volume":"192","author":"Lee","year":"2014","journal-title":"Lung"},{"key":"2024102404230499000_33.173.240058.94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.06.009"},{"key":"2024102404230499000_33.173.240058.95","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-2058"},{"key":"2024102404230499000_33.173.240058.96","doi-asserted-by":"publisher","DOI":"10.3201\/eid2108.141846"},{"key":"2024102404230499000_33.173.240058.97","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02469-2017"},{"key":"2024102404230499000_33.173.240058.98","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12109"},{"key":"2024102404230499000_33.173.240058.99","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.01.024"},{"key":"2024102404230499000_33.173.240058.100","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201304-085OC"},{"key":"2024102404230499000_33.173.240058.101","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01855-2016"},{"key":"2024102404230499000_33.173.240058.102","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/cid\/ciaa252","article-title":"Variability in the management of adults with pulmonary nontuberculous mycobacterial disease","volume":"72","author":"Abate","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024102404230499000_33.173.240058.103","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ccm.2023.07.005","article-title":"Investigation and management of bronchiectasis in nontuberculous mycobacterial pulmonary disease","volume":"44","author":"McShane","year":"2023","journal-title":"Clin Chest Med"},{"key":"2024102404230499000_33.173.240058.104","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00574-2020"},{"key":"2024102404230499000_33.173.240058.105","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.21037\/jtd-22-410","article-title":"Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review","volume":"14","author":"Youssefnia","year":"2022","journal-title":"J Thorac Dis"},{"key":"2024102404230499000_33.173.240058.106","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02053-2022"},{"key":"2024102404230499000_33.173.240058.107","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.07.019"},{"key":"2024102404230499000_33.173.240058.108","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02143-2018"},{"key":"2024102404230499000_33.173.240058.109","unstructured":"ClinicalTrials.gov . Hypertonic saline for MAC. Date last accessed: 1 March 2024. Date last updated: 19 December 2023. www.clinicaltrials.gov\/study\/NCT04921943"},{"key":"2024102404230499000_33.173.240058.110","unstructured":"ClinicalTrials.gov . Hypertonic saline inhalation for Mycobacterium avium complex pulmonary disease (SALINE). Date last accessed: 1 March 2024. Date last updated: 11 April 2023. www.clinicaltrials.gov\/study\/NCT05192057"},{"key":"2024102404230499000_33.173.240058.111","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00629-2017"},{"key":"2024102404230499000_33.173.240058.112","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-212463"},{"key":"2024102404230499000_33.173.240058.113","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-450OC"},{"key":"2024102404230499000_33.173.240058.114","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201604-246OC"},{"key":"2024102404230499000_33.173.240058.115","doi-asserted-by":"crossref","first-page":"107366","DOI":"10.1016\/j.rmed.2023.107366","article-title":"Monotherapy: key cause of macrolide-resistant Mycobacterium avium complex disease","volume":"217","author":"Loewenstein","year":"2023","journal-title":"Respir Med"},{"key":"2024102404230499000_33.173.240058.116","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00170-2018"},{"key":"2024102404230499000_33.173.240058.117","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1164\/rccm.202004-1418OC","article-title":"BACES score for predicting mortality in nontuberculous mycobacterial pulmonary disease","volume":"203","author":"Kim","year":"2020","journal-title":"Am J Respir Crit care Med"},{"key":"2024102404230499000_33.173.240058.118","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1016\/S1473-3099(21)00586-7","article-title":"Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases","volume":"22","author":"Lange","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024102404230499000_33.173.240058.119","doi-asserted-by":"crossref","first-page":"e01003-23","DOI":"10.1128\/aac.01003-23","article-title":"Comparison of treatment outcomes between intermittent and daily regimens in non-cavitary nodular bronchiectatic-type Mycobacterium avium complex pulmonary disease in relation to sputum smear results: a retrospective cohort study","volume":"67","author":"Jung","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102404230499000_33.173.240058.120","first-page":"A1035","article-title":"Intermittent versus daily treatment for noncavitary nodular bronchiectatic Mycobacteria avium complex lung disease with rifampicin, ethambutol, and clarithromycin (iREC): an open-label, multicenter, randomized controlled trial","volume":"209","author":"Fujita","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404230499000_33.173.240058.121","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2019-000434"},{"key":"2024102404230499000_33.173.240058.122","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1318OC"},{"key":"2024102404230499000_33.173.240058.123","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00610-2023"},{"key":"2024102404230499000_33.173.240058.124","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cmi.2023.02.007","article-title":"Towards clinical breakpoints for non-tuberculous mycobacteria \u2013 determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution","volume":"29","author":"Fr\u00f6berg","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2024102404230499000_33.173.240058.125","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1093\/cid\/ciaa1361","article-title":"Management of drug toxicity in M. avium complex pulmonary disease \u2013 an expert panel survey","volume":"73","author":"van Ingen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024102404230499000_33.173.240058.126","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00770-16"},{"key":"2024102404230499000_33.173.240058.127","doi-asserted-by":"crossref","first-page":"e00874-23","DOI":"10.1128\/aac.00874-23","article-title":"The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease","volume":"67","author":"Schildkraut","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102404230499000_33.173.240058.128","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201308-266OC"},{"key":"2024102404230499000_33.173.240058.129","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01787-19"},{"key":"2024102404230499000_33.173.240058.130","doi-asserted-by":"crossref","first-page":"106025","DOI":"10.1016\/j.rmed.2020.106025","article-title":"Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy","volume":"169","author":"Ito","year":"2020","journal-title":"Respir Med"},{"key":"2024102404230499000_33.173.240058.131","unstructured":"ClinicalTrials.gov . Comparison of two- versus three-antibiotic therapy for pulmonary Mycobacterium avium complex disease (MAC2v3). Date last accessed: 1 March 2024. Date last updated: 27 March 2024. www.clinicaltrials.gov\/study\/NCT03672630"},{"key":"2024102404230499000_33.173.240058.132","doi-asserted-by":"crossref","first-page":"e0115723","DOI":"10.1128\/aac.01157-23","article-title":"Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model","volume":"68","author":"Salillas","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102404230499000_33.173.240058.133","first-page":"462","article-title":"Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections \u00e0 Mycobact\u00e9ries","volume":"2","author":"Roussel","year":"1998","journal-title":"Int J Tuberc lung Dis"},{"key":"2024102404230499000_33.173.240058.134","doi-asserted-by":"publisher","DOI":"10.1378\/chest.15-0543"},{"key":"2024102404230499000_33.173.240058.135","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01505-12"},{"key":"2024102404230499000_33.173.240058.136","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00466-2021"},{"key":"2024102404230499000_33.173.240058.137","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.chest.2023.11.038","article-title":"Clofazimine is a safe and effective alternative for rifampicin in Mycobacterium avium complex pulmonary disease treatment \u2013 outcomes of a randomized trial","volume":"165","author":"Zweijpfenning","year":"2023","journal-title":"Chest"},{"key":"2024102404230499000_33.173.240058.138","unstructured":"ClinicalTrials.gov . Validation of patient reported outcome measures in participants with nontuberculous mycobacterial lung infection caused by Mycobacterium avium complex (ARISE). Date last accessed: 1 March 2024. Date last updated: 2 June 2023. www.clinicaltrials.gov\/study\/NCT04677543"},{"key":"2024102404230499000_33.173.240058.139","unstructured":"ClinicalTrials.gov . Study to evaluate ALIS (amikacin liposome inhalation suspension) in participants with nontuberculous mycobacterial lung infection caused by Mycobacterium avium complex (ENCORE). Date last accessed: 1 March 2024. Date last updated: 23 August 2023. www.clinicaltrials.gov\/study\/NCT04677569"},{"key":"2024102404230499000_33.173.240058.140","first-page":"A1033","article-title":"Microbiologic outcomes from a randomized, double-blind trial of amikacin liposome inhalation suspension in adults with newly diagnosed or recurrent Mycobacterium avium complex lung disease: the ARISE study","volume":"209","author":"Daley","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404230499000_33.173.240058.141","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.chest.2022.01.015","article-title":"Safety and outcomes of amikacin liposome inhalation suspension for Mycobacterium abscessus pulmonary disease: a NTM-NET study","volume":"162","author":"Zweijpfenning","year":"2022","journal-title":"Chest"},{"key":"2024102404230499000_33.173.240058.142","doi-asserted-by":"crossref","first-page":"ofac465","DOI":"10.1093\/ofid\/ofac465","article-title":"Amikacin liposomal inhalation suspension in the treatment of Mycobacterium abscessus lung infection: a French observational experience","volume":"9","author":"Chiron","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024102404230499000_33.173.240058.143","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.chest.2023.05.036","article-title":"Open-label trial of amikacin liposome inhalation suspension in Mycobacterium abscessus lung disease","volume":"164","author":"Siegel","year":"2023","journal-title":"Chest"},{"key":"2024102404230499000_33.173.240058.144","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0212-2021"},{"key":"2024102404230499000_33.173.240058.145","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0171-2021"},{"key":"2024102404230499000_33.173.240058.146","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000815","article-title":"New therapies for nontuberculous mycobacterial lung infection","volume":"35","author":"Chalmers","year":"2021","journal-title":"Curr Opin Infect Dis"},{"key":"2024102404230499000_33.173.240058.147","doi-asserted-by":"crossref","first-page":"e01144-22","DOI":"10.1128\/aac.01144-22","article-title":"Clofazimine inhalation suspension demonstrates promising toxicokinetics in canines for treating pulmonary nontuberculous mycobacteria infection","volume":"67","author":"Kunkel","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102404230499000_33.173.240058.148","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/jac\/dkad372","article-title":"Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis","volume":"79","author":"Omar","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2024102404230499000_33.173.240058.149","doi-asserted-by":"crossref","first-page":"ofad335","DOI":"10.1093\/ofid\/ofad335","article-title":"Long-term safety and tolerability of omadacycline for the treatment of Mycobacterium abscessus infections","volume":"10","author":"Mingora","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2024102404230499000_33.173.240058.150","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz511"},{"key":"2024102404230499000_33.173.240058.151","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s41030-022-00210-y","article-title":"Phage therapy for nontuberculous mycobacteria: challenges and opportunities","volume":"9","author":"Hatfull","year":"2023","journal-title":"Pulm Ther"},{"key":"2024102404230499000_33.173.240058.152","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12951"},{"key":"2024102404230499000_33.173.240058.153","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00724-2021"},{"key":"2024102404230499000_33.173.240058.154","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcf.2023.05.003","article-title":"Eradication of nontuberculous mycobacteria in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor: a multicenter cohort study","volume":"23","author":"Wiesel","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024102404230499000_33.173.240058.155","doi-asserted-by":"crossref","first-page":"1239151","DOI":"10.3389\/fimmu.2023.1239151","article-title":"Dipeptidyl peptidase 1 inhibition as a potential therapeutic approach in neutrophil-mediated inflammatory disease","volume":"14","author":"Chalmers","year":"2023","journal-title":"Front Immunol"},{"key":"2024102404230499000_33.173.240058.156","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N Engl J Med"},{"key":"2024102404230499000_33.173.240058.157","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00633-2022"},{"key":"2024102404230499000_33.173.240058.158","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00036704"},{"key":"2024102404230499000_33.173.240058.159","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200509-1531OC"},{"key":"2024102404230499000_33.173.240058.160","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-8-17"},{"key":"2024102404230499000_33.173.240058.161","doi-asserted-by":"publisher","DOI":"10.1086\/515249"},{"key":"2024102404230499000_33.173.240058.162","doi-asserted-by":"publisher","DOI":"10.1086\/315191"},{"key":"2024102404230499000_33.173.240058.163","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02127-2017"},{"key":"2024102404230499000_33.173.240058.164","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1513\/AnnalsATS.202306-532OC","article-title":"OPTIMA: an open-label, non-comparative pilot trial of inhaled molgramostim in pulmonary nontuberculous mycobacterial infection","volume":"21","author":"Thomson","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"2024102404230499000_33.173.240058.165","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jcf.2019.05.002","article-title":"Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection","volume":"19","author":"Bentur","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024102404230499000_33.173.240058.166","doi-asserted-by":"crossref","first-page":"e243979","DOI":"10.1136\/bcr-2021-243979","article-title":"Non-tuberculous mycobacteria infection treated with intermittently inhaled high-dose nitric oxide","volume":"14","author":"Goldbart","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2024102404230499000_33.173.240058.167","doi-asserted-by":"crossref","first-page":"107069","DOI":"10.1016\/j.rmed.2022.107069","article-title":"Inhaled nitric oxide for adults with pulmonary non-tuberculous mycobacterial infection","volume":"206","author":"Flume","year":"2023","journal-title":"Respir Med"},{"key":"2024102404230499000_33.173.240058.168","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001780"},{"key":"2024102404230499000_33.173.240058.169","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.3390\/microorganisms9122460","article-title":"T-cell exhaustion in Mycobacterium tuberculosis and nontuberculous mycobacteria infection: pathophysiology and therapeutic perspectives","volume":"9","author":"Lombardi","year":"2021","journal-title":"Microorganisms"},{"key":"2024102404230499000_33.173.240058.170","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00364-2022"},{"key":"2024102404230499000_33.173.240058.171","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000866"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0058-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:07:30Z","timestamp":1740355650000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0058-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":171,"journal-issue":{"issue":"173","published-online":{"date-parts":[[2024,7,3]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1183\/16000617.0058-2024"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0058-2024","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}